David F. Wiemer
Corporate Officer/Principal presso University of Iowa
Profilo
David F.
Wiemer is the founder of Terpenoid Therapeutics, Inc. which was founded in 2005.
He held the title of Director from 2012 to 2013.
Currently, he is a Professor at the University of Iowa.
Dr. Wiemer's education history includes an undergraduate degree from Marquette University and a doctorate from the University of Illinois.
Posizioni attive di David F. Wiemer
| Società | Posizione | Inizio |
|---|---|---|
| University of Iowa | Corporate Officer/Principal | - |
Precedenti posizioni note di David F. Wiemer
| Società | Posizione | Fine |
|---|---|---|
Terpenoid Therapeutics, Inc.
 Terpenoid Therapeutics, Inc. Medical DistributorsDistribution Services Terpenoid Therapeutics, Inc. operates as a biotechnology company focuses on anti-cancer therapeutics. The firm engages in creating, testing, and developing novel drug candidates using cutting-edge technologies. It is focused on discovering small molecule inhibitors of geranylgeranyl diphosphate synthase, a novel target with applicability towards cancer and other indication. The company was founded by Andrew J. Wiemer, Jeffery D. Neighbors, David F. Wiemer and Raymond J. Hohl in September 2005 and is headquartered in Coralville, IA. | Fondatore | - |
Formazione di David F. Wiemer
| Marquette University | Undergraduate Degree |
| University of Illinois | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
Terpenoid Therapeutics, Inc.
Terpenoid Therapeutics, Inc. Medical DistributorsDistribution Services Terpenoid Therapeutics, Inc. operates as a biotechnology company focuses on anti-cancer therapeutics. The firm engages in creating, testing, and developing novel drug candidates using cutting-edge technologies. It is focused on discovering small molecule inhibitors of geranylgeranyl diphosphate synthase, a novel target with applicability towards cancer and other indication. The company was founded by Andrew J. Wiemer, Jeffery D. Neighbors, David F. Wiemer and Raymond J. Hohl in September 2005 and is headquartered in Coralville, IA. | Distribution Services |
- Borsa valori
- Insiders
- David F. Wiemer
